Twentyeight-Seven Therapeutics launches with $65m to develop RNA-modulating cancer therapies

In an ambitious move within the biotechnology sector, a new U.S. biotech company, Twentyeight-Seven Therapeutics (28-7), has been established in Cambridge with a primary focus ... Read More